Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular CarcinomaMin Yu, Zonghai Li, Bizhi Shi et al.|Molecular Therapy|2017Cited by 184
Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion proteinZeyan Pan, Zonghai Li, Shengmeng Di et al.|Cancer Immunology Immunotherapy|2018Cited by 63